Neurosearch axe quarter of jobs in favour of lead drug

- Last updated on GMT

Neurosearch will slash a quarter of its workforce as plans roll ahead to refocus resources on its main product, the Huntington’s disease drug, Huntexil.

The Danish biopharma firm said the cost cuts, including the loss of 20 per cent of current employees, will reduce its annual outgoings by around 100m Danish crowns ($17m), with the full benefit being seen in 2012.

“The basis for the restructuring of Neurosearch is to ensure that optimal resources are placed behind Huntexil on its path towards commercialisation,”​ said the company.

Neurosearch revealed that drug discovery activities will be organised in a new division, NsDiscovery, which will maintain current alliances with Eli Lilly and Janssen, along with a licence agreement with Abbott.

Related topics: Clinical Development

Related news

Show more